Breast cancer survivors: could a common diabetes drug lower your risk?
NCT ID NCT06763328
First seen Jan 31, 2026 · Last updated Jun 17, 2026 · Updated 17 times
Summary
This study looks at whether metformin, a diabetes drug, can help prevent or reverse insulin resistance in women who finished chemotherapy for early-stage breast cancer. Insulin resistance raises the risk of diabetes and heart disease, and may also be linked to more aggressive breast cancer. About 80 women will either get metformin plus standard diet and exercise advice, or standard advice alone, and researchers will track their blood sugar levels over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UC San Diego Moores Cancer Center
NOT_YET_RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California-Riverside
NOT_YET_RECRUITINGRiverside, California, 92521, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.